The tablets are a new formulation of the drug lorcaserin, which is intended to help patients achieve and maintain weight loss when paired with a reduced-calorie diet and increased physical activity.
Arena, which entered into a licensing agreement with Tokyo-based Eisai in 2010, will receive a $10 million milestone payment for the approval.
Belviq XR is expected to reach the market in fall 2016.
More articles on the drug market:
PhRMA adds 5 new companies to its ranks, including generic rival Teva
Roche’s blood cancer drug disappoints in clinical trial
FDA approves Aurobindo’s new pain med
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
